Institutional members access full text with Ovid®

Share this article on:

European studies on long-term exposure to ambient particulate matter and lung cancer

Gallus, Silvanoa; Negri, Evaa; Boffetta, Paoloc; McLaughlin, Joseph K.d; Bosetti, Cristinaa; Vecchia, Carlo Laa b

European Journal of Cancer Prevention: June 2008 - Volume 17 - Issue 3 - p 191-194
doi: 10.1097/CEJ.0b013e3282f0bfe5
Reviews: Lung Cancer

European epidemiological studies on ambient air pollution and cancer published before December 2006 are reviewed, with focus on five analytic studies providing data on the association between various measures of particulate matter (PM) and lung cancer. A case–control study of 755 men who died from lung cancer in Trieste, Italy, reported that, compared with less than 0.18 g/m2/day of deposition of particulate, the relative risk (RR) was 1.1 [95% confidence interval (CI): 0.8–1.5] for 0.18–0.30 and 1.4 (95% CI: 1.1–1.8) for more than 0.30 g/m2/day. In the Netherlands Cohort Study on Diet and Cancer with 60 deaths from lung cancer, the RR was 1.06 (95% CI: 0.43–2.63) for an increase of 10 μg/m3 in black smoke. In the French Pollution Atmospherique et Affections Respiratoires Chroniques study cohort based on 178 deaths from lung cancer, the RR associated with an increase in exposure to 10 μg/m3 of total suspended particulate was 0.97 (95% CI: 0.94–1.01). A nested case–control study within the European Prospective Investigation on Cancer and Nutrition included 113 nonsmokers or exsmokers diagnosed with lung cancer and 312 controls. The RRs were 0.91 (95% CI: 0.70–1.18) for an increase in PM with diameter ≤10 μm (PM10) of 10 μg/m3, and 0.98 (95% CI: 0.66–1.45) for exposure over 27 μg/m3 compared with less than 27 μg/m3. In a Norwegian record linkage study, based on 1453 lung cancer deaths, no significant excess risk was found for men, and a modest association was observed for women. European studies of PM exposure and lung cancer do not show a clear association, but uncertainties remain for the measurement of exposure and latency.

a‘Mario Negri’ Institute for Pharmacological Research, Milan

b‘Giulio A. Maccacaro’ Institute of Medical Statistics and Biometry, University of Milan, Milan, Italy

cInternational Agency for Research on Cancer, Lyon, France

dInternational Epidemiology Institute, Rockville, Maryland, USA

Correspondence to Dr Silvano Gallus, Istituto di Ricerche Farmacologiche ‘Mario Negri’, Via La Masa 19, Milan, 20156, Italy

Tel: +39 02 39014 657; fax: +39 02 33200231;


Received 27 March 2007 Accepted 20 July 2007

© 2008 Lippincott Williams & Wilkins, Inc.